Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo
- 1 November 2001
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 8 (11), 869-878
- https://doi.org/10.1038/sj.cgt.7700387
Abstract
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.Keywords
This publication has 25 references indexed in Scilit:
- Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinomaThe Journal of Pathology, 1997
- Murine tissue inhibitor of metalloproteinases—4 (Timp—4): cDNA isolation and expression in adult mouse tissues1FEBS Letters, 1997
- Expression and in‐situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancerInternational Journal of Cancer, 1995
- Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreasGastroenterology, 1994
- Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasisThe FASEB Journal, 1993
- The Matrix Metalloproteinases and Their InhibitorsAmerican Journal of Respiratory Cell and Molecular Biology, 1992
- The matrix‐degrading metalloproteinasesBioEssays, 1992
- Inhibition of Collagenolytic Activity and Metastasis of Tumor Cells by a Recombinant Human Tissue Inhibitor of MetalloproteinasesJNCI Journal of the National Cancer Institute, 1990
- Tissue Inhibitor of Metalloproteinase (TIMP-2)Journal of Biological Chemistry, 1989
- Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activityNature, 1985